The exploratory methods in diagnosis of hyperplasia

Study on 72 typical hyperplasia patients, preservative drug treatment with progestin (Organmetril). The subjects were detailed examined, then were implemented exploratory tests, treated and followed-up regularly 3-6 months. Results: hyperplasia was common disease in all of aged of woman’s fertilizable period, with non-ovule menstruation cycle, specially in peri-menopause. Clinical feature was menorrhagia. To diagnose exactly, medical professionals required to combine exploratory methods as vaginal cytology, mucosal uterus ultrasound, uterus chamber endoscopy, ana-pathology of mucosal uterus piece,… in which ana-pathology of mucosal uterus piece had the most important role.

Comparing the treatment of menorrhagia caused of typical endometrial hyperplasia by progestin and some other methods

A study on 216 patients who had endometrial hyperplasia, these patients had been examined and treated from June 1999 to June 2004 at National hospital of Obstetrics and Gynecology. The patients were divided into 2 groups: Group 1 included 108 patients who were given Orgametril 5mgx 2 tablets/day; group 2 included 108 patients who received only consultation and follow up 6 months after being endometrium curetted. Results: After 6 months of treatment with progestin (Orgametril), there were only 3 patients in group 1 had pathological signs of endometrial hyperplasia (2.8%); 94 patients recovered completely (87%). In group 2, there were 74 patients recovered completely (64.8%) and 19 patients had pathological signs of endometrial hyperplasia (17.6%). After being treated, old patients had endometrium changed into menopause stage: atrophy, thinner and stop working, they also did not have menorrhagia anymore.

Evaluation of efficacy of rigevidon in treating pubertal menorrhagia at Institute for Protection of Mother and Newborn

Study on 80 symptomatic menorrhagia patients less than 18 years old treated at Institute for Protection of Mother and Newborn in the year 2000. Results: the rate of patients with irregular menstruation was highest (38.75%). 70% of patients lived in rural, so the rate of late hospital admission (>15 days) accounted for 73.75%. All patients suffered from anemia with 82.5% patients with moderate and severe anemia. Treatment with 2 tablets Rigevidon a day only one time in the evening until menorrhagia reduces, follows by 1 tablet a day for making artificial menstruation of 28 days, is effective in 96.25% patients. This finding showed that using Rigevidon for treating pubertal menorrhagia is simple, safe, and effective, no significant complication.